Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 26
Filter
1.
Oncotarget ; 7(38): 60986-60999, 2016 Sep 20.
Article in English | MEDLINE | ID: mdl-27533467

ABSTRACT

In both human chronic lymphocytic leukemia (CLL) and the New Zealand Black (NZB) murine model of CLL, decreased levels of microRNAs miR-15a/16 play an important role in the disease. Here we investigate the effects of this microRNA on early steps of B cell development and the capacity of miR-15a-deficient hematopoietic stem cells (HSC) and B1 progenitor cells (B1P) to reproduce CLL-like phenotype both in vitro and in vivo. Our results demonstrate that both miR-15a deficient HSC and B1P cells are capable of repopulating irradiated recipients and produce higher numbers of B1 cells than sources with normal miR-15a/16 levels. Furthermore, induced pluripotent stem (iPS) cells derived for the first time from NZB mice, provided insights into the B cell differentiation roadblock inherent in this strain. In addition, exogenously delivered miR-15a into the NZB derived B cell line provided valuable clues into novel targets such as Mmp10 and Mt2. Our data supports the hypothesis that miR-15a/16 deficient stem cells and B1Ps experience a maturation blockage, which contributes to B1 cells bias in development. This work will help understand the role of miR-15a in early events of CLL and points to B1P cells as potential cells of origin for this incurable disease.


Subject(s)
Leukemia, Lymphocytic, Chronic, B-Cell/metabolism , MicroRNAs/metabolism , Animals , Apoptosis/drug effects , B-Lymphocytes/metabolism , Cell Differentiation , Cell Line, Tumor , Cell Separation , Disease Models, Animal , Leukemia, Lymphocytic, Chronic, B-Cell/genetics , Lymphocyte Activation , Mice , Mice, Inbred BALB C , Mice, Inbred DBA , Neoplastic Stem Cells/metabolism , Stem Cells/metabolism
2.
Oncotarget ; 7(31): 49259-49267, 2016 Aug 02.
Article in English | MEDLINE | ID: mdl-27363032

ABSTRACT

Hepatocellular carcinoma (HCC) is the most prevalent type of liver cancer. No significant improvement has been reported with currently available systemic therapies. IFN-α has been tested in both clinic and animal models and only moderate benefits have been observed. In animal models, similar modest antitumor efficacy has also been reported for IFN-λ, a new type of IFN that acts through its own receptor complex. In the present study, the antitumor efficacy of the combination of IFN-α and IFN-λ was tested in the BNL mouse hepatoma model. This study was accomplished by using either engineered tumor cells (IFN-α/IFN-λ gene therapy) or by directly injecting tumor-bearing mice with IFN-α/IFN-λ. Both approaches demonstrated that IFN-α/IFN-λ combination therapy was more efficacious than IFN monotherapy based on either IFN-α or IFN-λ. In complement to tumor surgery, IFN-α/IFN-λ combination induced complete tumor remission. Highest antitumor efficacy has been obtained following local administration of IFN-α/IFN-λ combination at the tumor site that was associated with strong NK cells tumor infiltration. This supports the use of IFN-α/IFN-λ combination as a new cancer immunotherapy for stimulating antitumor response after cancer surgery.


Subject(s)
Carcinoma, Hepatocellular/metabolism , Interferon-alpha/metabolism , Interferon-gamma/metabolism , Killer Cells, Natural/cytology , Liver Neoplasms/metabolism , Animals , Carcinoma, Hepatocellular/immunology , Cell Proliferation , Cytotoxicity, Immunologic/drug effects , Female , Flow Cytometry , Genetic Therapy , Immunotherapy , Killer Cells, Natural/immunology , Leukocytes, Mononuclear/cytology , Liver Neoplasms/immunology , Mice , Mice, Inbred BALB C
3.
PLoS One ; 11(3): e0149331, 2016.
Article in English | MEDLINE | ID: mdl-26959643

ABSTRACT

New Zealand Black (NZB) mice, a de novo model of CLL, share multiple characteristics with CLL patients, including decreased expression of miR-15a/16-1. We previously discovered a point mutation and deletion in the 3' flanking region of mir-16-1 of NZB and a similar mutation has been found in a small number of CLL patients. However, it was unknown whether the mutation is the cause for the reduced miR-15a/16-1 expression and CLL development. Using PCR and in vitro microRNA processing assays, we found that the NZB sequence alterations in the mir-15a/16-1 loci result in deficient processing of the precursor forms of miR-15a/16-1, in particular, we observe impaired conversion of pri-miR-15a/16-1 to pre-miR-15a/16-1. The in vitro data was further supported by derivation of congenic strains with replaced mir-15a/16-1 loci at one or both alleles: NZB congenic mice (NmiR+/-) and DBA congenic mice (DmiR-/-). The level of miR-15a/16-1 reflected the configuration of the mir-15a/16-1 loci with DBA congenic mice (DmiR-/-) showing reduced miR-15a levels compared to homozygous wild-type allele, while the NZB congenic mice (NmiR+/-) showed an increase in miR-15a levels relative to homozygous mutant allele. Similar to Monoclonal B-cell Lymphocytosis (MBL), the precursor stage of the human disease, an overall expansion of the B-1 population was observed in DBA congenic mice (DmiR-/-) relative to wild-type (DmiR+/+). These studies support our hypothesis that the mutations in the mir-15a/16-1 loci are responsible for decreased expression of this regulatory microRNA leading to B-1 expansion and CLL development.


Subject(s)
B-Lymphocytes/pathology , Genetic Loci , Leukemia, Lymphocytic, Chronic, B-Cell/genetics , Leukemia, Lymphocytic, Chronic, B-Cell/pathology , MicroRNAs/genetics , RNA Processing, Post-Transcriptional , Animals , Base Sequence , Cell Line , Cell Proliferation , Disease Models, Animal , Mice , MicroRNAs/metabolism , Molecular Sequence Data , Mutation/genetics , Proteins/genetics , Side-Population Cells/metabolism , Spectroscopy, Fourier Transform Infrared , Spleen/metabolism , Transferases
4.
JAMA Oncol ; 1(8): 1061-8, 2015 Nov.
Article in English | MEDLINE | ID: mdl-26335650

ABSTRACT

IMPORTANCE: Multiple myeloma has been classified as exhibiting "limited or suggestive evidence" of an association with exposure to herbicides in Vietnam War veterans. Occupational studies have shown that other pesticides (ie, insecticides, herbicides, fungicides) are associated with excess risk of multiple myeloma and its precursor state, monoclonal gammopathy of undetermined significance (MGUS); however, to our knowledge, no studies have uncovered such an association in Vietnam War veterans. OBJECTIVE: To examine the relationship between MGUS and exposure to Agent Orange, including its contaminant 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), in Vietnam War veterans. DESIGN, SETTING, AND PARTICIPANTS: This was a prospective cohort study conducted in 2013 to 2014, testing for MGUS in serum specimens collected and stored in 2002 by the Air Force Health Study (AFHS). The relevant exposure data collected by the AFHS was also used. We tested all specimens in 2013 without knowledge of the exposure status. The AFHS included former US Air Force personnel who participated in Operation Ranch Hand (Ranch Hand veterans) and other US Air Force personnel who had similar duties in Southeast Asia during the same time period (1962 to 1971) but were not involved in herbicide spray missions (comparison veterans). Agent Orange was used by the US Air Force personnel who conducted aerial spray missions of herbicides (Operation Ranch Hand) in Vietnam from 1962 to 1971. We included 479 Ranch Hand veterans and 479 comparison veterans who participated in the 2002 follow-up examination of AFHS. EXPOSURES: Agent Orange and TCDD. Serum TCDD levels were measured in 1987, 1992, 1997, and 2002. MAIN OUTCOMES AND MEASURES: Risk of MGUS measured by prevalence, odds ratios (ORs), and 95% CIs. RESULTS: The 479 Ranch Hand veterans and 479 comparison veterans had similar demographic and lifestyle characteristics and medical histories. The crude prevalence of overall MGUS was 7.1% (34 of 479) in Ranch Hand veterans and 3.1% (15 of 479) in comparison veterans. This translated into a 2.4-fold increased risk for MGUS in Ranch Hand veterans than comparison veterans after adjusting for age, race, BMI in 2002, and the change in BMI between 2002 and the time of blood draw for TCDD measurement (adjusted OR, 2.37; 95% CI, 1.27-4.44; P=.007). CONCLUSIONS AND RELEVANCE: Operation Ranch Hand veterans have a significantly increased risk of MGUS, supporting an association between Agent Orange exposure and multiple myeloma.


Subject(s)
2,4,5-Trichlorophenoxyacetic Acid/adverse effects , 2,4-Dichlorophenoxyacetic Acid/adverse effects , Herbicides/adverse effects , Monoclonal Gammopathy of Undetermined Significance/chemically induced , Multiple Myeloma/chemically induced , Occupational Exposure/adverse effects , Polychlorinated Dibenzodioxins/adverse effects , Veterans Health , Vietnam Conflict , Aged , Aged, 80 and over , Agent Orange , Biomarkers/blood , Case-Control Studies , Humans , Logistic Models , Male , Middle Aged , Monoclonal Gammopathy of Undetermined Significance/blood , Monoclonal Gammopathy of Undetermined Significance/diagnosis , Monoclonal Gammopathy of Undetermined Significance/epidemiology , Multiple Myeloma/blood , Multiple Myeloma/diagnosis , Multiple Myeloma/epidemiology , Odds Ratio , Polychlorinated Dibenzodioxins/blood , Prevalence , Prospective Studies , Risk Assessment , Risk Factors , Time Factors , United States/epidemiology
5.
Stem Cells Dev ; 23(22): 2712-9, 2014 Nov 15.
Article in English | MEDLINE | ID: mdl-24964274

ABSTRACT

According to the endosymbiotic hypothesis, the precursor of mitochondria invaded the precursor of eukaryotic cells, a process that began roughly 2 billion years ago. Since then, the majority of the genetic material translocated from the mitochondria to the nucleus, where now almost all mitochondrial proteins are expressed. Only a tiny amount of DNA remained in the mitochondria, known as mitochondrial DNA (mtDNA). In this study, we report that the transfer of mtDNA fragments to the nucleus of pluripotent stem cells is still ongoing. We show by in situ hybridization and agarose DNA two-dimensional gel technique that induced pluripotent stem (iPS) cells contain high levels of mtDNA in the nucleus. We found that a large proportion of the accumulated mtDNA sequences appear to be extrachromosomal. Accumulation of mtDNA in the nucleus is present not only in the iPS cells, but also in embryonic stem (ES) cells. However upon differentiation, the level of mtDNA in the nuclei of iPS and ES cells is substantially reduced. This reversible accumulation of mtDNA in the nucleus supports the notion that the nuclear copy number of mtDNA sequences may provide a novel mechanism by which chromosomal DNA is dynamically regulated in pluripotent stem cells.


Subject(s)
Cell Nucleus/metabolism , DNA, Mitochondrial/metabolism , Induced Pluripotent Stem Cells/metabolism , Mitochondria/metabolism , Animals , Biological Transport/physiology , Cell Differentiation/physiology , Cell Line , Chromosomes/genetics , DNA, Mitochondrial/genetics , Embryonic Stem Cells/metabolism , Gene Dosage/genetics , Mice , Mice, Inbred C57BL
6.
Leuk Res Treatment ; 2012: 603830, 2012.
Article in English | MEDLINE | ID: mdl-23259069

ABSTRACT

Common blood disorders include hematopoietic cell malignancies or leukemias and plasma cell dyscrasia, all of which have associated microRNA abnormalities. In this paper, we discuss several leukemias including acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL) and identify altered microRNAs and their targets. Immune disorders with altered blood levels of antibodies include autoimmune disorders, such as systemic lupus erythematosus (SLE) with associated anti-self-autoantibodies and immunoglobulin A nephropathy (IgAN) also have related microRNA abnormalities. The alterations in microRNAs may serve as therapeutic targets in these blood disorders.

7.
J Biomed Biotechnol ; 2012: 758169, 2012.
Article in English | MEDLINE | ID: mdl-22619497

ABSTRACT

Human disease animal models are absolutely invaluable tools for our understanding of mechanisms involved in both physiological and pathological processes. By studying various genetic abnormalities in these organisms we can get a better insight into potential candidate genes responsible for human disease development. To this point a mouse represents one of the most used and convenient species for human disease modeling. Hundreds if not thousands of inbred, congenic, and transgenic mouse models have been created and are now extensively utilized in the research labs worldwide. Importantly, pluripotent stem cells play a significant role in developing new genetically engineered mice with the desired human disease-like phenotype. Induced pluripotent stem (iPS) cells which represent reprogramming of somatic cells into pluripotent stem cells represent a significant advancement in research armament. The novel application of microRNA manipulation both in the generation of iPS cells and subsequent lineage-directed differentiation is discussed. Potential applications of induced pluripotent stem cell--a relatively new type of pluripotent stem cells--for human disease modeling by employing human iPS cells derived from normal and diseased somatic cells and iPS cells derived from mouse models of human disease may lead to uncovering of disease mechanisms and novel therapies.


Subject(s)
Disease Models, Animal , Induced Pluripotent Stem Cells/physiology , MicroRNAs/genetics , Animals , Humans , Mice , Mice, Transgenic , Transplantation, Heterologous
8.
Mol Immunol ; 52(2): 61-70, 2012 Sep.
Article in English | MEDLINE | ID: mdl-22578383

ABSTRACT

MicroRNAs (miRNAs) are involved in the regulation of immunity via targeting of mRNA encoding immune response elements. In this report, alterations in the expression of microRNAs as autoantibody levels increase was investigated. The (NZB×NZW)F1 or B/W mouse model of systemic lupus erythematosus (SLE) naturally has increased autoantibodies with aging. IFNα (type I IFN) accelerates B/W disease, however, the effects of a related IFN, IFNλ, which is a type III IFN, is largely unknown. The purpose of the study was to investigate the relationship between IFN-accelerated disease, microRNAs, immunoregulatory B cell subsets and autoantibody production in the autoimmune-prone environment in vivo. B/W mice received osmotic pumps to chronically deliver IFNα and IFNλ for up to 16 weeks. Urine protein level was monitored weekly by urine strips and proteinuria was used as the disease marker. Splenic cells were taken for flow analysis of B cell subsets and levels of microRNAs determined. Plasma were analyzed for autoantibodies and microRNA levels. As a result of treatment, IFNα accelerated proteinuria in a dose dependent manner, while IFNλ single treatment did not show a significant effect, but greatly enhanced low dose IFNα effects in the combination treatment. Both the splenic cellular and plasma miR-15a were elevated in diseased compared to pre-diseased mice as well as autoantibody levels. Autoantibodies and miR-15a levels were significantly correlated. The immunosuppressive B subpopulation, B-10, was reduced following IFNα treatment. In addition in diseased mice, B-10 versus B-2 ratios were reduced in IFN-treated B/W compared to the control PBS treated group. In all B/W the miR-15a was highly expressed in the B-10 subset and this increased with disease development, suggesting that miR-15a has a specific negative effect on the B-10 subpopulation. In conclusion, our data support the involvement of elevated miR-15a in autoimmune disease development in B/W mice and suggest that decreasing this microRNA might be beneficial in B/W mice.


Subject(s)
Autoantibodies/biosynthesis , Lupus Erythematosus, Systemic/genetics , Lupus Erythematosus, Systemic/immunology , MicroRNAs/genetics , MicroRNAs/immunology , Animals , B-Lymphocyte Subsets/immunology , B-Lymphocyte Subsets/pathology , Base Sequence , DNA Primers/genetics , Disease Models, Animal , Female , Interferon-alpha/administration & dosage , Interferons/administration & dosage , Interferons/classification , Lupus Erythematosus, Systemic/etiology , Lupus Erythematosus, Systemic/pathology , Mice , Mice, Inbred NZB , MicroRNAs/blood , MicroRNAs/metabolism , Recombinant Proteins/administration & dosage , Spleen/immunology , Spleen/pathology , Up-Regulation/drug effects
9.
Cytometry B Clin Cytom ; 78 Suppl 1: S10-8, 2010.
Article in English | MEDLINE | ID: mdl-20839330

ABSTRACT

BACKGROUND: Individuals with monoclonal B-cell lymphocytosis (MBL) have been identified in clinic outpatients, in unaffected relatives of patients with chronic lymphocytic leukemia (CLL), and in general populations. MBL and its relationship with CLL have been actively investigated over the last decade. This report systematically reviews the prevalence of MBL in the context of the populations studied and the evolution of laboratory methods used to define MBL. METHODS: To identify published studies that have assessed the prevalence of MBL, we systematically searched the MEDLINE databases and consulted with members of the International MBL Study Group. We reviewed the 10 articles that were identified by this process. We abstracted information on study populations, laboratory tests, criteria for designating MBL, and the reported frequencies. RESULTS: Three of the ten studies were published in 2009, three between 2007 and 2008, and four between 2002 and 2004. Reported prevalences varied widely, ranging from 0.12 to 18.2%. This variability was clearly associated with both the laboratory methods and the populations studied. MBL was more common among older individuals and kindred of persons with CLL. The most common MBL subtype was CLL-like MBL. CONCLUSIONS: Large population-based studies of MBL that employ standardized laboratory methods with a consensus case definition are needed to assess prevalence and establish risk factors. These studies should include prospective follow-up of MBL cases to determine the relationship between MBL and CLL. Data from original studies should be reported in sufficient detail to allow future synthesis of information from multiple studies, such as meta-analysis.


Subject(s)
B-Lymphocytes/pathology , Lymphocytosis/epidemiology , Clone Cells , Female , Global Health , Humans , Leukemia, Lymphocytic, Chronic, B-Cell/immunology , Leukemia, Lymphocytic, Chronic, B-Cell/pathology , Lymphocyte Count , Lymphocytosis/immunology , Lymphocytosis/pathology , MEDLINE , Male , Prevalence
10.
Cytometry B Clin Cytom ; 78 Suppl 1: S98-109, 2010.
Article in English | MEDLINE | ID: mdl-20839343

ABSTRACT

BACKGROUND: Similar to a subset of human patients who progress from monoclonal B lymphocytosis (MBL) to chronic lymphocytic leukemia (CLL), New Zealand Black (NZB) mice have an age-associated progression to CLL. The murine disease is linked to a genetic abnormality in microRNA mir-15a/16-1 locus, resulting in decreased mature miR-15a/16. METHODS: Spleens of aging NZB were analyzed for the presence of B-1 cells via flow cytometry and for the presence of a side population (SP) via the ability of cells to exclude Hoechst 33342 dye. The SP was assayed for the presence of hyperdiploid B-1 clones and for the ability to differentiate into B-1 cells in vitro and transfer disease in vivo. In addition, enhanced apoptosis of chemoresistant NZB B-1 cells was examined by restoring miR-16 levels in nutlin-treated cells. RESULTS: Aging NZB mice develop a B-1 expansion and clonal development that evolves from MBL into CLL. An expansion in SP is also seen. Although the SP did contain increased cells with stem cell markers, they lacked malignant B-1 cells and did not transfer disease in vivo. Similar to B-1 cells, splenic NZB SP also has decreased miR-15a/16 when compared with C57Bl/6. Exogenous addition of miR-15a/16 to NZB B-1 cells resulted in increased sensitivity to nutlin. CONCLUSION: NZB serve as an excellent model for studying the development and progression of age-associated CLL. NZB SP cells do not seem to contain cancer stem cells, but rather the B-1 stem cell. NZB B-1 chemoresistance may be related to reduced miR-15a/16 expression.


Subject(s)
Leukemia, Lymphocytic, Chronic, B-Cell/pathology , Age Factors , Animals , Apoptosis/drug effects , Cell Separation , Cell Survival , Disease Models, Animal , Disease Progression , Female , Flow Cytometry , Imidazoles/pharmacology , Immunophenotyping , Leukemia, Lymphocytic, Chronic, B-Cell/immunology , Male , Mice , Mice, Inbred C57BL , Mice, Inbred NZB , Piperazines/pharmacology , Spleen/drug effects , Spleen/immunology , Spleen/pathology
11.
Cancer Immunol Immunother ; 59(7): 1059-71, 2010 Jul.
Article in English | MEDLINE | ID: mdl-20217081

ABSTRACT

Hepatocellular carcinoma (HCC) occurs most commonly secondary to cirrhosis due to chronic hepatitis C or B virus (HCV/HBV) infections. Type I interferon (IFN-alpha) treatment of chronic HCV/HBV infections reduces the incidence of HCC in cirrhotic patients. However, IFN-alpha toxicity limits its tolerability and efficacy highlighting a need for better therapeutic treatments. A recently discovered type III IFN (IFN-lambda) has been shown to possess antiviral properties against HCV and HBV in vitro. In phase I clinical trials, IFN-lambda treatment did not cause significant adverse reactions. Using a gene therapy approach, we compared the antitumor properties of IFN-alpha and IFN-lambda in a transplantable hepatoma model of HCC. BALB/c mice were inoculated with syngeneic BNL hepatoma cells, or BNL cells expressing IFN-lambda (BNL.IFN-lambda cells) or IFN-alpha (BNL.IFN-alpha cells). Despite the lack of antiproliferative activity of IFNs on BNL cells, both BNL.IFN-lambda and BNL.IFN-alpha cells displayed retarded growth kinetics in vivo. Depletion of NK cells from splenocytes inhibited splenocyte-mediated cytotoxicity, demonstrating that NK cells play a role in IFN-induced antitumor responses. However, isolated NK cells did not respond directly to IFN-lambda. There was also a marked NK cell infiltration in IFN-lambda producing tumors. In addition, IFN-lambda and, to a lesser extent, IFN-alpha enhanced immunocytotoxicity of splenocytes primed with irradiated BNL cells. Splenocyte cytotoxicity against BNL cells was dependent on IL-12 and IFN-gamma, and mediated by dendritic cells. In contrast to NK cells, isolated from spleen CD11c+ and mPDCA+ dendritic cells responded directly to IFN-lambda. The antitumor activities of IFN-lambda against hepatoma, in combination with HCV and HBV antiviral activities warrant further investigation into the clinical use of IFN-lambda to prevent HCC in HCV/HBV-infected cirrhotic patients, as well as to treat liver cancer.


Subject(s)
Cell Proliferation/drug effects , Interferon Type I/pharmacology , Interferons/pharmacology , Liver Neoplasms, Experimental/prevention & control , Animals , Antineoplastic Agents/pharmacology , Cell Line, Tumor , Cytotoxicity, Immunologic/immunology , Dendritic Cells/cytology , Dendritic Cells/immunology , Female , Flow Cytometry , Immunohistochemistry , Interferon Type I/genetics , Interferons/classification , Interferons/genetics , Interleukin-12/metabolism , Killer Cells, Natural/cytology , Killer Cells, Natural/immunology , Liver Neoplasms, Experimental/immunology , Liver Neoplasms, Experimental/pathology , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Neoplasm Transplantation , STAT1 Transcription Factor/immunology , STAT1 Transcription Factor/metabolism , Spleen/cytology , Spleen/immunology , Spleen/metabolism , Transfection
12.
Mol Cancer Ther ; 8(9): 2684-92, 2009 Sep.
Article in English | MEDLINE | ID: mdl-19723889

ABSTRACT

Alterations in the human 13q14 genomic region containing microRNAs mir-15a and mir-16-1 are present in most human chronic lymphocytic leukemia (CLL). We have previously found the development of CLL in the New Zealand Black murine model to be associated with a point mutation in the primary mir-15a/16-1 region, which correlated with a decrease in mature miR-16 and miR-15a levels. In this study, addition of exogenous miR-15a and miR-16 led to an accumulation of cells in G(1) in non-New Zealand Black B cell and New Zealand Black-derived malignant B-1 cell lines. However, the New Zealand Black line had significantly greater G(1) accumulation, suggesting a restoration of cell cycle control upon exogenous miR-15a/16 addition. Our experiments showed a reduction in protein levels of cyclin D1, a miR-15a/16 target and cell cycle regulator of G(1)/S transition, in the New Zealand Black cell line following miR-15a/16 addition. These microRNAs were shown to directly target the cyclin D1 3' untranslated region using a green fluorescent protein lentiviral expression system. miR-16 was also shown to augment apoptosis induction by nutlin, a mouse double minute 2 (MDM2) antagonist, and genistein, a tyrosine kinase inhibitor, when added to a B-1 cell line derived from multiple in vivo passages of malignant B-1 cells from New Zealand Black mice with CLL. miR-16 synergized with nutlin and genistein to induce apoptosis. Our data support a role for the mir-15a/16-1 cluster in cell cycle regulation and suggest that these mature microRNAs in both the New Zealand Black model and human CLL may be targets for therapeutic efficacy in this disease.


Subject(s)
Disease Models, Animal , Leukemia, Lymphocytic, Chronic, B-Cell/genetics , MicroRNAs/genetics , Animals , Antineoplastic Agents/pharmacology , Apoptosis , Base Sequence , Cyclin D1/genetics , DNA Primers , Drug Screening Assays, Antitumor , Genistein/therapeutic use , Imidazoles/therapeutic use , Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy , Leukemia, Lymphocytic, Chronic, B-Cell/pathology , Mice , Mice, Inbred C57BL , Piperazines/therapeutic use , RNA, Messenger/genetics
13.
J Autoimmun ; 32(1): 14-23, 2009 Feb.
Article in English | MEDLINE | ID: mdl-19022624

ABSTRACT

Regulatory T cells (Tregs) play an important role in protection against autoimmune disease and are also known to be potent inhibitors of anti-tumor immune responses. The New Zealand Black (NZB) mouse is a murine model for both autoimmune diseases, since high levels of autoantibodies are present, and human CLL, due to the expansion of malignant B-1 cells. In this study, we examined the functional role of CD4(+)CD25(+) Foxp3(+) Tregs in these different manifestations. Flow cytometric analysis showed increased levels of Tregs in NZB mice compared to healthy C57Bl/6 controls. Aged NZB mice that have developed a B-1 cell malignancy identified as IgM(+)CD5(+), have the most pronounced increase in Tregs. Ex vivo treatment of splenocytes from NZB mice with IFN-alpha resulted in a decrease in the frequency of Tregs and malignant B-1 cells. In vivo treatment of both NZB and C57Bl/6 mice with poly (I:C), a potent inducer of IFN-alpha, also led to a decrease in the levels of Tregs and malignant B-1 cells (NZB only) while amplifying autoimmune manifestations. These results indicate that while high levels of Tregs found in NZB mice might suppress a more severe autoimmune disease, they may also contribute to the development of the B cell malignancy.


Subject(s)
Autoimmune Diseases/immunology , Autoimmunity/immunology , Leukemia, B-Cell/immunology , Leukemia, B-Cell/pathology , T-Lymphocytes, Regulatory/immunology , Age Factors , Animals , Antibodies/blood , Antibodies/immunology , Antibodies/pharmacology , Antibodies, Antinuclear/blood , Ascitic Fluid/cytology , Ascitic Fluid/immunology , Autoimmune Diseases/pathology , B-Lymphocytes/cytology , B-Lymphocytes/drug effects , B-Lymphocytes/immunology , Erythrocytes/immunology , Forkhead Transcription Factors/genetics , Immune Tolerance/immunology , Interferon-alpha/blood , Interferon-alpha/pharmacology , Interferons/genetics , Interferons/pharmacology , Interleukin-10/blood , Interleukin-10/genetics , Interleukin-2 Receptor alpha Subunit/immunology , Lymph Nodes/cytology , Lymph Nodes/immunology , Mice , Mice, Inbred C57BL , Mice, Inbred NZB , Poly I-C/pharmacology , Spleen/cytology , Spleen/drug effects , Spleen/immunology , T-Lymphocyte Subsets/cytology , T-Lymphocyte Subsets/drug effects , T-Lymphocyte Subsets/immunology , T-Lymphocyte Subsets/metabolism , T-Lymphocytes, Regulatory/cytology , T-Lymphocytes, Regulatory/drug effects , T-Lymphocytes, Regulatory/metabolism , ZAP-70 Protein-Tyrosine Kinase/genetics
14.
Biochemistry ; 47(46): 12018-27, 2008 Nov 18.
Article in English | MEDLINE | ID: mdl-18937499

ABSTRACT

Type I interferons (IFNs) are multifunctional cytokines that activate cellular responses by binding a common receptor consisting of two subunits, IFNAR-1 and IFNAR-2. Although the binding of IFNs to IFNAR-2 is well characterized, the binding to the lower affinity IFNAR-1 remains less well understood. Previous reports identified a region of human IFN-alpha2 on the B and C helices ("site 1A": N65, L80, Y85, Y89) that plays a key role in binding IFNAR-1 and contributes strongly to differential activation by various type I IFNs. The current studies demonstrate that residues on the D helix are also involved in IFNAR-1 binding. In particular, residue 120 (Arg in IFN-alpha2; Lys in IFN-alpha2/alpha1) appears to be a "hot-spot" residue: substitution by alanine significantly decreased biological activity, and the charge-reversal mutation of residue 120 to Glu caused drastic loss of antiviral and antiproliferative activity for both IFN-alpha2 and IFN-alpha2/alpha1. Mutations in residues of helix D maintained their affinity for IFNAR-2 but had decreased affinity for IFNAR-1. Single-site or multiple-site mutants in the IFNAR-1 binding site that had little or no detectable in vitro biological activity were capable of blocking in vitro antiviral and antiproliferative activity of native IFN-alpha2; i.e., they are type I IFN antagonists. These prototype IFN antagonists can be developed further for possible therapeutic use in systemic lupus erythematosus, and analogous molecules can be designed for use in animal models.


Subject(s)
Interferon-alpha/antagonists & inhibitors , Receptor, Interferon alpha-beta/chemistry , Amino Acid Substitution , Animals , Binding Sites/genetics , Cattle , Disease Models, Animal , Humans , Interferon-alpha/chemistry , Interferon-alpha/genetics , Interferon-alpha/metabolism , Lupus Erythematosus, Systemic/drug therapy , Lupus Erythematosus, Systemic/genetics , Lupus Erythematosus, Systemic/metabolism , Mice , Protein Binding/genetics , Protein Structure, Secondary/genetics , Receptor, Interferon alpha-beta/genetics , Receptor, Interferon alpha-beta/metabolism
15.
Br J Haematol ; 139(5): 630-4, 2007 Dec.
Article in English | MEDLINE | ID: mdl-18021078

ABSTRACT

Although the familial aspect of chronic lymphocytic leukaemia (CLL) has been appreciated for decades, it is only with the recent confluence of improved molecular and gene technologies and world-wide collaborative networks that accelerated progress has become apparent. In this summary we highlight selected themes in the genetics of CLL emphasizing the opportunities and challenges of this malignancy.


Subject(s)
Leukemia, Lymphocytic, Chronic, B-Cell/genetics , Chromosome Aberrations , Epigenesis, Genetic , Genetic Predisposition to Disease , Humans , Leukemia, Lymphocytic, Chronic, B-Cell/ethnology , Lymphocytosis/genetics , MicroRNAs/genetics , Precancerous Conditions/genetics , Prognosis , RNA, Neoplasm/genetics
16.
Br J Haematol ; 139(5): 701-8, 2007 Dec.
Article in English | MEDLINE | ID: mdl-18021084

ABSTRACT

Monoclonal B-cell lymphocytosis (MBL) has been the subject of more intensive investigation for the last 10 years. The increased presence of MBL in unaffected, first-degree relatives with familial chronic lymphocytic leukaemia (CLL) suggest that it is surrogate marker for early disease. In normal population studies, MBL is found to be increased in ageing subjects. Consensus criteria for the diagnosis of MBL have been proposed. The differential diagnosis has been further clarified and the prevalence of MBL is most prominent in the elderly. The aetiology of MBL is unknown but probably involves immune mechanism of senescence or altered response. Environmental health studies suggest that exposure to certain toxins may lead to MBL but further work is needed. MBL is a precursor to CLL but may also regress, remain stable or progress to clinical CLL.


Subject(s)
B-Lymphocytes , Lymphocytosis/diagnosis , Diagnosis, Differential , Disease Progression , Environmental Health , Humans , Leukemia, Lymphocytic, Chronic, B-Cell/diagnosis , Leukemia, Lymphocytic, Chronic, B-Cell/etiology , Leukemia, Lymphocytic, Chronic, B-Cell/genetics , Lymphocytosis/etiology , Lymphocytosis/genetics , Pedigree
17.
Br J Haematol ; 139(5): 820-3, 2007 Dec.
Article in English | MEDLINE | ID: mdl-17941936

ABSTRACT

Monoclonal B cell lymphocytosis (MBL) was detected in four unaffected first-degree relatives (FDR) in a familial chronic lymphocytic leukaemia (CLL) kindred. The proband remains untreated and two male siblings have died. The four unaffected siblings have been followed for a five-year period. All four FDR developed a kappa(+)CD5(+) MBL detected by flow cytometry. Poymerase chain reaction (PCR) for IGHV rearrangement showed evidence of oligoclonality in three of these individuals. Single cell PCR of flow cytometric sorted kappa(+) cells combined with Ig kappa light chain gene sequencing revealed further evidence of monoclonality in two of these individuals. Three of these individuals all showed evidence of hyper-somatic mutations. The B-cell repertoire in unaffected FDR in familial CLL offers a new area to investigate the interface between the immune system and lymphoid neoplasm.


Subject(s)
B-Lymphocytes , Leukemia, Lymphocytic, Chronic, B-Cell/genetics , Lymphocytosis/genetics , Neoplastic Stem Cells/pathology , CD5 Antigens/blood , Female , Flow Cytometry/methods , Follow-Up Studies , Gene Rearrangement, B-Lymphocyte , Genes, Immunoglobulin Heavy Chain , Genes, Immunoglobulin Light Chain , Genetic Predisposition to Disease , Humans , Leukemia, Lymphocytic, Chronic, B-Cell/immunology , Lymphocytosis/immunology , Male , Mutation , Polymerase Chain Reaction/methods
18.
Br J Haematol ; 139(5): 645-57, 2007 Dec.
Article in English | MEDLINE | ID: mdl-17941951

ABSTRACT

Mouse models are valuable tools in the study of human chronic lymphocytic leukaemia (CLL). The New Zealand Black (NZB) strain is a naturally occurring model of late-onset CLL characterized by B-cell hyperproliferation and autoimmunity early in life, followed by progression to CLL. Other genetically engineered models of CLL that have been developed include (NZB x NZW) F1 mice engineered to express IL5, mice expressing human TCL1A, and mice overexpressing both BCL2 and a tumour necrosis factor receptor-associated factor. The applicability to human CLL varies with each model, suggesting that CLL is a multifactorial disease. Our work with the de novo NZB model has revealed many similarities to the human situation, particularly familial CLL. In NZB, the malignant clones express CD5, zap-70, and have chromosomal instability and germline Ig sequence. We also identified a point mutation in the 3'-flanking sequence of Mirn16-1, which resulted in decreased levels of the microRNA, miR-16 in lymphoid tissue. Exogenous restoration of miR-16 to an NZB malignant B-1 cell line resulted in cell cycle alterations, suggesting that the altered expression of Mirn15a/16-1 is an important molecular lesion in CLL. Future studies utilizing the NZB mouse could ascertain the role of environmental triggers, such as low dose radiation and organic chemicals in the augmentation of a pre-existing propensity to develop CLL.


Subject(s)
Disease Models, Animal , Leukemia, Lymphocytic, Chronic, B-Cell/genetics , MicroRNAs/genetics , RNA, Neoplasm/genetics , Animals , Base Sequence , Mice , Mice, Inbred NZB , Mice, Transgenic , Molecular Sequence Data , Point Mutation
19.
Blood ; 109(12): 5079-86, 2007 Jun 15.
Article in English | MEDLINE | ID: mdl-17351108

ABSTRACT

New Zealand black (NZB) mice with autoimmune and B lymphoproliferative disease (B-LPD) are a model for human chronic lymphocytic leukemia (CLL). A genomewide linkage scan of the NZB loci associated with lymphoma was conducted in F1 backcrosses of NZB and a control strain, DBA/2. Of 202 mice phenotyped for the presence or absence of LPD, surface maker expression, DNA content, and microsatellite polymorphisms, 74 had disease. The CD5(+), IgM(+), B220(dim), hyperdiploid LPD was linked to 3 loci on chromosomes 14, 18, and 19 that are distinct from previously identified autoimmunity-associated loci. The region of synteny with mouse D14mit160 is the human 13q14 region, associated with human CLL, containing microRNAs mir-15a16-1. DNA sequencing of multiple NZB tissues identified a point mutation in the 3' flanking sequence of the identical microRNA, mir-16-1, and this mutation was not present in other strains, including the nearest neighbor, NZW. Levels of miR-16 were decreased in NZB lymphoid tissue. Exogenous miR-16 delivered to an NZB malignant B-1 cell line resulted in cell-cycle alterations and increased apoptosis. Linkage of the mir-15a/16-1 complex and the development of B-LPD in this spontaneous mouse model suggest that the altered expression of the mir-15a/16-1 is the molecular lesion in CLL.


Subject(s)
Chromosomes, Human, Pair 13/genetics , Leukemia, Lymphocytic, Chronic, B-Cell/genetics , MicroRNAs/genetics , Point Mutation , Synteny/genetics , Animals , Apoptosis/drug effects , Apoptosis/genetics , B-Lymphocytes , Cell Cycle/drug effects , Cell Cycle/genetics , Chromosomes, Mammalian , DNA/analysis , Humans , Lymphoproliferative Disorders/genetics , Mice , Mice, Inbred NZB , MicroRNAs/pharmacology , Polymorphism, Genetic
20.
Cancer Immunol Immunother ; 56(4): 501-14, 2007 Apr.
Article in English | MEDLINE | ID: mdl-17051411

ABSTRACT

The role of ZAP-70 expression on the ex vivo response of blood cells from CLL and PLL patients to a combination of fludarabine, a purine analog, and genistein, a tyrosine kinase inhibitor was studied. Patient cells were studied for the expression of ZAP-70 mRNA and its relation to the induction of apoptosis in response to treatment with genistein 15-60 muM and/or fludarabine 3 muM. The combination of genistein and fludarabine resulted in a significantly increased induction of apoptosis relative to the fludarabine alone. The ex vivo patient cells with a high ZAP-70 expression underwent more apoptosis in response to genistein than did patient cells with a low ZAP-70 mRNA expression. In contrast, basal IL-10 mRNA expression correlated negatively with apoptosis induction in response to genistein (P < 0.01). These studies suggest that, in malignant B cells that express elevated levels of the ZAP-70 signaling molecule, genistein may inhibit the ZAP-70 tyrosine kinase activity, resulting in cell death. The ZAP-70 may serve as a target for therapy. In addition, these studies suggest that the IL-10 expression by malignant B cells may not only suppress anti-tumor T cell responses in vivo, but also promote the survival of malignant B cells despite treatment with chemotherapeutic agents.


Subject(s)
Antineoplastic Agents/pharmacology , Apoptosis/physiology , Leukemia, B-Cell/metabolism , ZAP-70 Protein-Tyrosine Kinase/biosynthesis , Aged , Aged, 80 and over , Flow Cytometry , Gene Expression/drug effects , Gene Expression Profiling , Genistein/pharmacology , Humans , Interleukin-10/biosynthesis , Male , Middle Aged , RNA, Messenger/analysis , Reverse Transcriptase Polymerase Chain Reaction , Vidarabine/analogs & derivatives , Vidarabine/pharmacology , ZAP-70 Protein-Tyrosine Kinase/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...